Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PolyTherics has extended its collaboration with a top five pharmaceutical company to further investigate applications of its polymer, PolyPEG.
Subscribe to our email newsletter
PolyPEG , a patented polymer increases the half-life in the body of therapeutic proteins to which it is bound.
As part of the collaboration, the properties of different proteins will be assessed following conjugation to a range of PolyPEG polymers of different molecular architectures.
The evaluations will include in vitro binding and activity assays with proteins targeted to a number of disease areas. Selected PolyPEG protein conjugates will also be evaluated in imaging and pharmacokinetic studies.
PolyTherics CEO John Burt said the addition of PolyPEG helps the company to produce better biopharmaceuticals and has also attracted the interest of several major pharmaceutical and biotechnology companies looking to develop enhanced and differentiated biopharmaceutical products.
”We are therefore delighted to extend this current collaboration with a top five pharmaceutical company to evaluate the applicability of our technologies across a wide range of proteins," Burt added.